Fortune 500 Power Moves: Which executives gained and lost power, Aug. 8-21

Zoetis (ZTS) reported flat Q2 revenue of $2.47B, missing estimates, and lowered full-year guidance. Supernus Pharmaceuticals (SUPN) reported 27.7% revenue growth to $211.3M, beating estimates. Eli Lilly (LLY) reported 47.7% revenue growth to $22.97B, significantly beating estimates. All three stocks have risen since reporting.

Zoetis (ZTS) stock rose 3.61% in a day and 6.52% in a week after FDA authorized Simparica Trio for treating New World screwworm. Despite recent gains, shares are down 38.27% year-to-date and 48.95% in a year. The company lowered revenue and earnings guidance, with a 11% YoY decline in U.S. Companion Animal segment revenue. ValueInvestingSubstack values Zoetis at $92.92, suggesting a 16.3% undervaluation.

GE HealthCare Technologies reported an 11.1% year-over-year increase in organic orders for Q2, with a record backlog of $23.9 billion. Orders grew across all segments, and 85% of Q3 equipment revenue is already secured. The company reaffirmed its full-year revenue growth guidance of 3% to 4%, but execution and inflation remain key challenges.

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

Zoetis Inc. (NYSE:ZTS) received emergency authorization for Simparica Trio to treat New World screwworm in dogs. This follows a 7% decline in U.S. revenue and 11% drop in domestic companion-animal product sales. The authorization expands the product's use, potentially supporting its lifecycle amid competitive pressure and macroeconomic sensitivity.

Zoetis (NYSE:ZTS) reported flat Q2 2026 revenue of $2.5B, down 1% organically, with U.S. companion-animal sales declining 11% due to price sensitivity and competition. Livestock and international sales grew 12% and 8%, respectively. The company highlighted a pipeline of 12 potential blockbuster products and recent acquisitions to drive future growth.